Active, not recruitingPhase 4NCT05181618
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Studying Moderate hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Emicizumab(drug)
- Enrollment
- 136 enrolled
- Eligibility
- 13-69 years · All sexes
- Timeline
- 2022 – 2027
Study locations (28)
- Orthopaedic Institute for Children, Los Angeles, California, United States
- University of Miami Medical Center, Miami, Florida, United States
- Oklahoma Children's Hospital ? Jimmy Everest Center, Oklahoma City, Oklahoma, United States
- Hospital das Clinicas - UNICAMP, Campinas, São Paulo, Brazil
- Hospital das Clínicas Faculdades Médicas de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil
- Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
- Charité Universitätsklinikum Berlin, Berlin, Germany
- Universitätsklinikum Bonn, Bonn, Germany
- Észak-Pesti Centrumkórház - Honvédkórház, Budapest, Hungary
- AOU Federico II, Naples, Campania, Italy
- Policlinico Univ. A. Gemelli, Rome, Lazio, Italy
- IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy
- AOU Careggi, Florence, Tuscany, Italy
- Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat, Morocco
- University Clinical Centre of Serbia, Belgrade, Serbia
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05181618 on ClinicalTrials.govOther trials for Moderate hemophilia A
Additional recruiting or active studies for the same condition.